Paper Details

  1. Home
  2. Paper Details

Evaluation of alpha-difluoromethylornithine as a potential chemopreventive agent: tolerance to daily oral administration in humans.

Author: CreavenP J, PendyalaL, PetrelliN J

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

Alpha-difluoromethylornithine (DFMO) is a drug used to prevent cancer. In a clinical trial, 27 subjects received DFMO for 6 months. The highest nontoxic dose was 1600 mg/m2/day. Common side effects were hearing loss, diarrhea, fatigue, joint pain, insomnia, and rash.
Paper Details　
Original Abstract of the Article :
An initial clinical trial of alpha-difluoromethylornithine given p.o. daily for 6 months was carried out in 27 subjects free of disease following surgery for malignancy or in a defined high-risk group for cancer. The aim was to determine the highest nontoxic dose, principal side effects, and pharmac...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/8318877

データ提供：米国国立医学図書館（NLM）

Alpha-Difluoromethylornithine: A Potential Chemopreventive Agent

Cancer is a devastating disease that affects millions of people around the world. In the field of [cancer prevention], we are constantly searching for ways to reduce the risk of developing cancer. This study explored the potential of alpha-difluoromethylornithine as a chemopreventive agent.

The researchers conducted a clinical trial to determine the safety and effectiveness of alpha-difluoromethylornithine in humans. The study found that the drug was well-tolerated at doses up to 1600 mg/m2/day. This is like finding a safe path through the desert, a route that can lead to cancer prevention.

A New Approach to Cancer Prevention

This research provides a new avenue for cancer prevention. It's like finding a hidden oasis in the desert of cancer research, a place where we can find new ways to prevent this disease. This study suggests that alpha-difluoromethylornithine could be a promising chemopreventive agent.

Protecting Against Cancer

This research highlights the importance of exploring new approaches to cancer prevention. It's like finding a new way to navigate the desert of cancer research, a route that leads to a healthier future. By continuing to research new chemopreventive agents, we can work towards a world where cancer is less of a threat.

Dr.Camel's Conclusion

This research shows the potential of alpha-difluoromethylornithine as a chemopreventive agent. It’s like finding a new oasis in the desert of cancer prevention, a place where we can find hope for a healthier future.

Date :
  1. Date Completed 1993-08-03
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

8318877

DOI: Digital Object Identifier

8318877

Related Literature

Article Analysis
・Side Effects of eflornithine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.